Diffusion Pharmaceuticals Announces Validation of European Patent for Oral Formulations of TSC

Pharmaceutical Investing

Diffusion Pharmaceuticals (NASDAQ:DFFN) a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, today announced the validation of European Patent No.: 2 575 487, entitled “Oral Formulations of Bipolar Trans Carotenoids.” As quoted in the press release: This patent is directed to oral formulations of bipolar trans carotenoids including trans sodium crocetinate …

As quoted in the press release:

This patent is directed to oral formulations of bipolar trans carotenoids including trans sodium crocetinate (“TSC”). Embodiments of the invention include the novel compositions in the form of a tablet, pill or capsule. The claims also include compositions for the treatment of hypoxia caused by many disorders. This European Patent is based on the same patent application that was allowed by the U.S. Patent and Trademark Office (PTO) in January 2018.

Click here to read the full press release.

diffusion pharmaceuticals nasdaq:dffn Pharmaceutical Investing